Cancer Research and Treatment

Original Articles

Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer: Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2006;38(1):19-24. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.19

Purpose

It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.

Materials and Methods

We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%).

Results

Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008).

Conclusion

The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed.

Citations

Citations to this article as recorded by

Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
Chunchao Zhu, Qin Yang, Jia Xu, Wenyi Zhao, Zizhen Zhang, Danhua Xu, Yeqian Zhang, Enhao Zhao, Gang Zhao
Journal of Translational Medicine.2019;[Epub] CrossRef
The design, analysis and application of mouse clinical trials in oncology drug development
Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li
BMC Cancer.2019;[Epub] CrossRef
Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu
Cancer Biomarkers.2018; 21(2): 439. CrossRef
The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy
Jianning Song, Jie Yin, Zhigang Bai, Jun Zhang, Hua Meng, Jun Cai, Wei Deng, Xuemei Ma, Zhongtao Zhang
Digestive Diseases and Sciences.2017; 62(5): 1223. CrossRef
Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
Qiang Xu, Zuofu Zhang, Weixue Sun, Baiqiang Hu
Mammalian Genome.2017; 28(5-6): 227. CrossRef
Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis
PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO
Experimental and Therapeutic Medicine.2015; 9(4): 1393. CrossRef
Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107. CrossRef
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer
Yalei Zhang, Haihong Yang, Yuan Qiu, Qiuhua Deng, Jun Liu, Meiling Zhao, Ping He, Mingcong Mo, Xusen Zou, Jianxing He
Medical Oncology.2014;[Epub] CrossRef
The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
Tumor Biology.2014; 35(9): 8721. CrossRef
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
Cancer Chemotherapy and Pharmacology.2013; 72(1): 159. CrossRef
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma
Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El‐Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel
Cancer.2013; 119(17): 3242. CrossRef
GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
Hui-Yan Li, Xin Ge, Guang-Ming Huang, Kai-Yu Li, Jing-Quan Zhao, Xi-Miao Yu, Wen-Si Bi, Yu-Lin Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3465. CrossRef
Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
Ting Hao, Wei Feng, Jie Zhang, Yong-Jian Sun, Gang Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3821. CrossRef
The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture
Roderich E. Schwarz, John C. Mansour
Annals of Surgical Oncology.2012; 19(7): 2081. CrossRef
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim
Biomarkers.2011; 16(1): 74. CrossRef
ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer
Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
Future Oncology.2010; 6(11): 1735. CrossRef
Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim
British Journal of Cancer.2009; 100(5): 732. CrossRef

12,935 View
61 Download
17 Crossref

Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer: Jae Jin Lee, Si-Young Kim, Im sik Shin, Kyung Sam Cho, Hoong-Zae Joo, Choong Yoon, Yoon Wha Kim, Hwi Joong Yoon; Cancer Res Treat. 2004;36(2):140-145. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.140

Abstract PDF PubReader ePub

Purpose

The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.

Methods

From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.

Results

54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.

Conclusions

This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

Citations

Citations to this article as recorded by

Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
Tom van den Ende, Emil ter Veer, Mélanie Machiels, Rosa M. A. Mali, Frank A. Abe Nijenhuis, Laura de Waal, Marety Laarman, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(1): 80. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
Gastric Cancer.2018; 21(6): 1031. CrossRef
Current challenges of metastatic breast cancer
Bora Lim, Gabriel N. Hortobagyi
Cancer and Metastasis Reviews.2016; 35(4): 495. CrossRef
Management of Gastroesophageal Junction Tumors
Matthew P. Fox, Victor van Berkel
Surgical Clinics of North America.2012; 92(5): 1199. CrossRef

9,822 View
61 Download
7 Crossref

Prognostic Effect of Vascular Endothelial Growth Factor and Angiogenesis in Gastric Carcinoma: Myoung Im Kim, Si Young Kim, Jae Jin Lee, Hwi Joong Yoon, Yoon Wha Kim, Kyung Sam Cho; Cancer Res Treat. 2003;35(3):218-223. Published online June 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.3.218

Abstract PDF

PURPOSE
Many studies have shown that angiogenesis has an important role in the growth, progression, and metastasis of solid tumors. Recently, several angiogenic factors have been identified. Vascular endothelial growth factor (VEGF) is a well characterized inducer of angiogenesis. In this study, we investigated the prognostic significance of the expression of VEGF in patients with an advanced gastric carcinoma. MATERIALS AND METHODS: Specimens from 54 gastric adenocarcinoma patients were stained using a polyclonal antibody against VEGF. Correlations of the expression of VEGF, microvessel density, and various other clinicopathological factors were analysed. RESULTS: Seventeen (31.5%) and 37 cases (68.5%) were VEGF-negative and positive, respectively. There was significant correlation between the expression of VEGF and pathological differentiation. There were no significant correlations between the expression of VEGF, stage and recurrence of a gastric carcinoma. The microvessel density was significantly higher in the VEGF-positive than the VEGF-negative tumors. Survivals of the VEGF-negative patients were significantly prolonged compared to those of the VEGF-positive patients. CONCLUSION: The results of this study show that the expression of VEGF may be a useful prognostic factor for patients with a gastric adenocarcinoma.

Citations

Citations to this article as recorded by

RETRACTED ARTICLE: KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis
Changhwan Yoon, Jun Lu, Yukyung Jun, Yun-Suhk Suh, Bang-Jin Kim, Jacob E. Till, Jong Hyun Kim, Sara H. Keshavjee, Sandra Ryeom, Sam S. Yoon
BMC Cancer.2023;[Epub] CrossRef
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
Jong Gwang Kim, Yee Soo Chae, Sang Kyun Sohn, Yoon Young Cho, Joon Ho Moon, Jae Yong Park, Seoung Woo Jeon, In Taek Lee, Gyu Seog Choi, Soo-Han Jun
Clinical Cancer Research.2008; 14(1): 62. CrossRef

3,934 View
19 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search